The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic AstrocytomaJuliane L. Buhl, Till Milde, Jan Gronych et al.|Clinical Cancer Research|2018Cited by 84
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemiaCornelis M. van Tilburg, Olaf Witt, Till Milde et al.|Clinical Epigenetics|2019Cited by 44
Table S5 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic AstrocytomaJuliane L. Buhl, Till Milde, Florian Selt et al.|Unknown|2023Cited by 0
Figure S1, Figure S2, Figure S3, Figure S4 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic AstrocytomaJuliane L. Buhl, Till Milde, Florian Selt et al.|Unknown|2023Cited by 0
Table S5 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic AstrocytomaJuliane L. Buhl, Till Milde, Christel Herold‐Mende et al.|Unknown|2023Cited by 0